Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Orion Office REIT Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Orion Office REIT Inc trades at $2.11 (market cap $119.79M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 8.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Orion Office REIT Inc for 34 Days on average.
| MRVI | ONL | |
|---|---|---|
Market Cap | $972.90M | $119.79M |
Volume | 4,325,710 | 378,596 |
Sector | Health | Real Estate |
52-Week High | $9.00 | $3.00 |
52-Week Low | $2.83 | $1.93 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $1.08B | $536.73M |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
ONL trades at $2.10, down 2.33% today, with a bearish technical signal from moving averages. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear mixed with low P/S (0.84) and P/B (0.19) ratios but negative profitability margins. Analyst consensus is evenly split between Buy and Hold ratings.
The outlook remains challenging due to ongoing revenue declines and negative margins, though the deep discount to book value and recent earnings beat offer potential upside. Key risks include high debt levels, weak office property demand, and sustained cash flow pressures. Investors should weigh the value proposition against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
